189 related articles for article (PubMed ID: 1344660)
1. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis.
Calzavara-Pinton P; Ortel B; Carlino A; Honigsmann H; De Panfilis G
Exp Dermatol; 1992 Jul; 1(1):46-51. PubMed ID: 1344660
[TBL] [Abstract][Full Text] [Related]
2. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
[TBL] [Abstract][Full Text] [Related]
3. Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation.
Aubin F; Makki S; Humbert P; Muret P; Agache P
Arch Dermatol Res; 1994; 286(1):30-4. PubMed ID: 8141609
[TBL] [Abstract][Full Text] [Related]
4. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
Berg M; Ros AM
Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
[TBL] [Abstract][Full Text] [Related]
6. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
Hönigsmann H; Jaschke E; Gschnait F; Brenner W; Fritsch P; Wolff K
Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
[TBL] [Abstract][Full Text] [Related]
7. Photochemotherapy (PUVA) and psoriasis: comparison of 8-MOP and 8-MOP/5-MOP.
Langner A; Wolska H; Kowalski J; Duralska H; Murawska E
Int J Dermatol; 1976 Nov; 15(9):688-9. PubMed ID: 977210
[TBL] [Abstract][Full Text] [Related]
8. Determination of 8-methoxypsoralen kinetics: a relevant factor in the treatment of psoriasis by psoralen plus ultraviolet A therapy.
Bonnot D; Béani JC; Boitard M; Reymond JL; Bériel H; Amblard P
Photodermatol Photoimmunol Photomed; 1994 Feb; 10(1):33-7. PubMed ID: 8180098
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and dose-response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical application of three standard preparations.
Grundmann-Kollmann M; Tegeder I; Ochsendorf FR; Zollner TM; Ludwig R; Kaufmann R; Podda M
Br J Dermatol; 2001 May; 144(5):991-5. PubMed ID: 11359386
[TBL] [Abstract][Full Text] [Related]
10. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
Tanew A; Ortel B; Rappersberger K; Hönigsmann H
J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
[TBL] [Abstract][Full Text] [Related]
11. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.
McNeely W; Goa KL
Drugs; 1998 Oct; 56(4):667-90. PubMed ID: 9806110
[TBL] [Abstract][Full Text] [Related]
12. 5-Methoxy psoralen, etretinate, and UVA for psoriasis.
Lane-Brown M
Int J Dermatol; 1987 Dec; 26(10):655-9. PubMed ID: 3429102
[TBL] [Abstract][Full Text] [Related]
13. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis.
Collins P; Rogers S
Br J Dermatol; 1992 Oct; 127(4):392-5. PubMed ID: 1419760
[TBL] [Abstract][Full Text] [Related]
14. [Clinical experience with the 8-methoxypsoralen-UVA therapy (photochemotherapy) of psoriasis].
Hofmann C; Plewig G; Braun-Falco O
Hautarzt; 1976 Dec; 27(12):588-94. PubMed ID: 1010746
[TBL] [Abstract][Full Text] [Related]
15. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.
Collins P; Wainwright NJ; Amorim I; Lakshmipathi T; Ferguson J
Br J Dermatol; 1996 Aug; 135(2):248-54. PubMed ID: 8881668
[TBL] [Abstract][Full Text] [Related]
16. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
George SA; Ferguson J
Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
[TBL] [Abstract][Full Text] [Related]
17. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA.
Hannuksela-Svahn A; Pukkala E; Koulu L; Jansén CT; Karvonen J
J Am Acad Dermatol; 1999 May; 40(5 Pt 1):694-6. PubMed ID: 10321595
[TBL] [Abstract][Full Text] [Related]
18. Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination.
Calzavara-Pinton P
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):687-90. PubMed ID: 9591811
[TBL] [Abstract][Full Text] [Related]
19. Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).
Ravenscroft J; Goulden V; Wilkinson M
J Am Acad Dermatol; 2001 Dec; 45(6 Suppl):S218-9. PubMed ID: 11712064
[TBL] [Abstract][Full Text] [Related]
20. The relationship between plasma psoralen concentration and psoralen-UVA erythema.
Mclelland J; Fisher C; Farr PM; Diffey BL; Cox NH
Br J Dermatol; 1991 Jun; 124(6):585-90. PubMed ID: 2064944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
